Bausch Health Companies vs Teva Pharmaceutical Industries
BHC and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and TEVA compare
Teva Pharmaceutical Industries is the larger company, worth 16 times as much as Bausch Health Companies ($50.9B against $3.1B).
Bausch Health Companies grew revenue faster over the last twelve months (10.8% versus −15.2% for Teva Pharmaceutical Industries).
Teva Pharmaceutical Industries keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with −7.6% at Bausch Health Companies.
Bausch Health Companies scores higher on the StockData Score (8 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $50.9B |
| Share price | $8.35 | $43.65 |
| Change, 1 year | 20.3% | 73.7% |
| Change, 5 years | −67.9% | 392% |
| Beta (5Y) | 1.00 | 0.98 |
| Employees | 20K | 34K |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 72.8× |
| P/S | 0.3× (better) | 3.6× |
| P/B | – | 6.6× |
| EV/EBITDA | 9.3× (better) | 20.0× |
| P/FCF | 1.7× (better) | 37.7× |
| FCF yield | 59.7% (better) | 2.7% |
| Fair value | $37.02 | $19.90 |
| Margin of safety | 77.4% (better) | −119% |
| Growth | ||
| Revenue growth (TTM) | 10.8% (better) | −15.2% |
| Revenue growth, 5Y average | 5.0% (better) | 0.71% |
| Net income growth (TTM) | −332% | – |
| EPS growth (TTM) | −336% | – |
| Profitability | ||
| Gross margin | – | 64.4% |
| Operating margin | 11.2% | 11.4% (better) |
| Net margin | −7.6% | 5.0% (better) |
| FCF margin | 16.8% (better) | 9.6% |
| Return on equity | – | 9.7% |
| Return on invested capital | 5.5% | 23.0% (better) |
| Financial health | ||
| Debt / equity | – | 0.58 |
| Net debt / EBITDA | 7.57 | 0.33 (better) |
| Interest coverage | 0.8× | – |
| Current ratio | 1.56 (better) | 0.88 |
| Altman Z-score | 0.22 | 0.89 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 63.4% | – |
| Held by insiders | 31.5% | 0.41% |
| Insider net buying, 12 months | −$507K (better) | −$124M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.9% | 2.4% |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.